CA2224002A1 - Facteur de croissance 3 de l'endothelium vasculaire humain - Google Patents

Facteur de croissance 3 de l'endothelium vasculaire humain Download PDF

Info

Publication number
CA2224002A1
CA2224002A1 CA002224002A CA2224002A CA2224002A1 CA 2224002 A1 CA2224002 A1 CA 2224002A1 CA 002224002 A CA002224002 A CA 002224002A CA 2224002 A CA2224002 A CA 2224002A CA 2224002 A1 CA2224002 A1 CA 2224002A1
Authority
CA
Canada
Prior art keywords
polypeptide
polynucleotide
vegf3
dna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002224002A
Other languages
English (en)
Inventor
Jing-Shan Hu
Henrik Olsen
Craig A. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP95922260A priority Critical patent/EP0873348A4/fr
Priority to PCT/US1995/007283 priority patent/WO1996039421A1/fr
Priority to CA002224002A priority patent/CA2224002A1/fr
Publication of CA2224002A1 publication Critical patent/CA2224002A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un polypeptide VEGF3 humain ainsi que l'ADN (ARN) codant ce type de polypeptides VEGF3. L'invention concerne également une procédure de production d'un tel polypeptide par des techniques de recombinaison ainsi que des anticorps et des antagonistes actifs vis-à-vis d'un tel polypeptide. L'invention concerne en outre un procédé d'utilisation d'un tel polypeptide dans le but d'accélérer la cicatrisation et de réparer des tissus vasculaires. L'invention concerne également des procédés d'utilisation desdits antagonistes pour inhiber la croissance des tumeurs, l'inflammation et pour traiter la rétinopathie diabétique, la polyarthrite rhumatoïde et le psoriasis. L'invention concerne en outre des procédés de diagnostic permettant de déceler des mutations dans la séquence de codage des VEGF3, de même que des modifications de la concentration de la protéine VEGF3 dans un échantillon prélevé sur un sujet hôte.
CA002224002A 1995-06-06 1995-06-06 Facteur de croissance 3 de l'endothelium vasculaire humain Abandoned CA2224002A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95922260A EP0873348A4 (fr) 1995-06-06 1995-06-06 Facteur de croissance 3 de l'endothelium vasculaire humain
PCT/US1995/007283 WO1996039421A1 (fr) 1995-06-06 1995-06-06 Facteur de croissance 3 de l'endothelium vasculaire humain
CA002224002A CA2224002A1 (fr) 1995-06-06 1995-06-06 Facteur de croissance 3 de l'endothelium vasculaire humain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/007283 WO1996039421A1 (fr) 1995-06-06 1995-06-06 Facteur de croissance 3 de l'endothelium vasculaire humain
CA002224002A CA2224002A1 (fr) 1995-06-06 1995-06-06 Facteur de croissance 3 de l'endothelium vasculaire humain

Publications (1)

Publication Number Publication Date
CA2224002A1 true CA2224002A1 (fr) 1996-12-12

Family

ID=25679907

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002224002A Abandoned CA2224002A1 (fr) 1995-06-06 1995-06-06 Facteur de croissance 3 de l'endothelium vasculaire humain

Country Status (3)

Country Link
EP (1) EP0873348A4 (fr)
CA (1) CA2224002A1 (fr)
WO (1) WO1996039421A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
ATE459715T1 (de) 1995-09-29 2010-03-15 Univ Siena Regulierte gene und ihre verwendungen
ATE306546T1 (de) 1996-08-23 2005-10-15 Ludwig Inst Cancer Res Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
KR20010020259A (ko) * 1997-04-25 2001-03-15 컬래터럴 테러퓨틱스 말단이 잘린 ｖｅｇｆ-관련 단백질
GB2324960A (en) * 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
WO1999040197A2 (fr) 1998-02-06 1999-08-12 Collateral Therapeutics, Inc. Variants du facteur angiogenique de croissance cellulaire endotheliale vasculaire vegf
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
AU770899B2 (en) 1998-11-10 2004-03-04 Licentia Ltd Platelet-derived growth factor D, DNA coding therefor, and uses thereof
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
JPH11500139A (ja) * 1995-03-02 1999-01-06 アムラド・オペレイションズ・プロプライエタリー・リミテッド 新規成長因子およびそれをコードする遺伝子配列

Also Published As

Publication number Publication date
EP0873348A1 (fr) 1998-10-28
WO1996039421A1 (fr) 1996-12-12
EP0873348A4 (fr) 2000-11-08

Similar Documents

Publication Publication Date Title
EP0837934B1 (fr) Facteur de croissance endotheliale vasculaire 2 humain
US7227005B1 (en) Vascular endothelial growth factor 2
US7576189B2 (en) Antibodies to human vascular endothelial growth factor 2 and methods of using the same
US20040086967A1 (en) Human criptin growth factor
US20070154908A1 (en) Connective Tissue Growth Factor-2
JP2007244388A5 (fr)
CA2224002A1 (fr) Facteur de croissance 3 de l'endothelium vasculaire humain
US20060068474A1 (en) Endothelial-monocyte activating polypeptide III
US20050256050A1 (en) Vascular endothelial growth factor 2
US20090311263A1 (en) Human vascular ibp-like growth factor
US20020102634A1 (en) Human stanniocalcin-alpha
AU714165B2 (en) Human criptin growth factor
AU716100B2 (en) Human vascular endothelial growth factor 3
US20020098515A1 (en) Cytostatin I
AU762694B2 (en) Human criptin growth factor
AU2005200574A1 (en) Human Vascular Endothelial Factor 2
AU2780600A (en) Human vascular endothelial growth factor 3
CA2413012A1 (fr) Facteur de croissance endotheliale vasculaire 2 humain
EP0873349A1 (fr) Polypeptide de type iii activateur des monocytes et des cellules endotheliales
CA2215286A1 (fr) Criptine humaine: facteur de croissance
AU2003252757A1 (en) Human Criptin Growth Factor
MXPA97009570A (en) Growth factor 3 endothelial, vascular, hum
AU1541402A (en) Human vascular endothelial growth factor 2
AU1951100A (en) Human vascular endothelial growth factor 2
CA2242964A1 (fr) Cytokine de cellule immunitaire

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead